Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00583986 · ClinicalTrials.gov registry record · Phase 3
Reliability of a Top Mount Actuation Indicator With Levalbuterol MDI in Adult and Pediatric Subjects With Asthma or COPD
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
NCT00583986 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 150 participants.
The verdict
NCT00583986, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
Study Summary
This is a study to investigate the reliability, ruggedness and safety of the top mounted actuation indicator (TMAI) when used with Levalbuterol HFA MDI.
Interventions
- DRUG Levalbuterol HFA MDI with top mounted actuation indicator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2005-09 |
| Est. Completion | 2006-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00583986
The ClinicalTrials.gov registry entry for NCT00583986 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Levalbuterol HFA MDI with top mounted actuation indicator is the first listed.
NCT00583986 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00583986 about?
NCT00583986 is a clinical study titled "Reliability of a Top Mount Actuation Indicator With Levalbuterol MDI in Adult and Pediatric Subjects With Asthma or COPD". This is a study to investigate the reliability, ruggedness and safety of the top mounted actuation indicator (TMAI) when used with Levalbuterol HFA MDI.
What is the current status of trial NCT00583986?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2005-09. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00583986?
The interventions under investigation include: Levalbuterol HFA MDI with top mounted actuation indicator (DRUG).
Who is sponsoring clinical trial NCT00583986?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.